1.82
-0.045(-2.42%)
Currency In USD
| Previous Close | 1.86 |
| Open | 1.86 |
| Day High | 1.92 |
| Day Low | 1.82 |
| 52-Week High | 6.15 |
| 52-Week Low | 1.63 |
| Volume | 29,262 |
| Average Volume | 67,232 |
| Market Cap | 8.49M |
| PE | -0.63 |
| EPS | -2.9 |
| Moving Average 50 Days | 2.34 |
| Moving Average 200 Days | 2.49 |
| Change | -0.05 |
If you invested $1000 in BioCardia, Inc. (BCDA) 10 years ago, it would be worth $3.57 as of April 25, 2025 at a share price of $1.815. Whereas If you bought $1000 worth of BioCardia, Inc. (BCDA) shares 5 years ago, it would be worth $11.93 as of April 25, 2025 at a share price of $1.815.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial
GlobeNewswire Inc.
Apr 15, 2025 12:30 PM GMT
Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of participants treated in low dosage group. The company plans to progress the trial to enrollment of 39 participant
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
GlobeNewswire Inc.
Apr 11, 2025 1:15 PM GMT
CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress Dr. Arshed Quyyumi, Professor of Medicine, Division of Cardiology, D
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
GlobeNewswire Inc.
Mar 31, 2025 5:39 PM GMT
SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF re